Loss of Effective Antigen Presentation in Melanoma and Treatment Failure
Loss of effective presentation of tumor antigens by melanoma may drive immunotherapy resistance. We will use multiplex immunofluorescence to map antigen presentation at single-cell resolution across whole slides, and correlate spatial expression with genomic and transcriptomic studies and patient outcomes. Samples from the The Cancer Genome Atlas (TCGA) as well as patient samples taken before and during immunotherapy will be studied to develop prognostic and predictive biomarkers.
— Joel C. Sunshine, M.D., Ph.D.
- Johns Hopkins School of Medicine
- Dermatopathology Research Career Development Award
Categories: Featured Researchers
Tags: 2021 Research Awards, Immunotherapy, Melanoma, Tumor Immunology
Exploring Gene Expression Patterns and Biomarkers of Disease Severity in Central Centrifugal Cicatricial Alopecia
Central centrifugal cicatricial alopecia (CCCA), which has been associated with uterine fibroids, is unlike other scarring alopecias because fibrosis rather…
Characterizing the Microbiome in Postmenopausal Women with Vulvar Lichen Sclerosus
Vulvar lichen sclerosus is a chronic inflammatory condition that leads to scarring, obliteration of normal vulvar architecture, dyspareunia, and significant…
Cell Signaling Changes Induced by Surgical Debulking May Improve Response to Smoothened Inhibitor Therapy
Smoothened (SMO) inhibitors, such as vismodegib, are effective treatments for locally advanced basal cell carcinomas (BCCs). However, recurrences are frequent…